Edition:
United Kingdom

Zogenix Inc (ZGNX.OQ)

ZGNX.OQ on NASDAQ Stock Exchange Global Market

40.90USD
19 Apr 2018
Change (% chg)

$0.05 (+0.12%)
Prev Close
$40.85
Open
$40.50
Day's High
$41.67
Day's Low
$40.10
Volume
122,952
Avg. Vol
160,686
52-wk High
$45.80
52-wk Low
$10.05

Chart for

About

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008,... (more)

Overall

Beta: 2.01
Market Cap(Mil.): $1,207.95
Shares Outstanding(Mil.): 31.54
Dividend: --
Yield (%): --

Financials

  ZGNX.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -3.38 -- --
ROI: -39.41 1.58 14.38
ROE: -70.89 2.41 16.07

BRIEF-Zogenix Inc Q4 Loss Per Share $1.17

* ZOGENIX PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

06 Mar 2018

BRIEF-Zogenix Completes Enrollment In Second ZX008 Phase 3 Clinical Trial In Dravet Syndrome

* ZOGENIX COMPLETES ENROLLMENT IN SECOND ZX008 PHASE 3 CLINICAL TRIAL IN DRAVET SYNDROME

31 Jan 2018

BRIEF-Zogenix Says May Issue And Sell Shares Of Common Stock Having An Aggregate Offering Price Of Up To $75.0 Mln

* ZOGENIX INC - MAY ISSUE AND SELL SHARES OF COMMON STOCK HAVING AN AGGREGATE OFFERING PRICE OF UP TO $75.0 MILLION Source text: (http://bit.ly/2kHM2Eb) Further company coverage:

22 Dec 2017

BRIEF-Zogenix Announces New Data From Pivotal Phase 3 Clinical Trial Of ZX008

* ZOGENIX ANNOUNCES NEW POSITIVE EFFICACY AND SAFETY DATA FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF ZX008 IN DRAVET SYNDROME

04 Dec 2017

BRIEF-Zogenix posts Q3 loss of $1.68 per share

* Zogenix provides corporate update and reports third quarter 2017 financial results

07 Nov 2017

Earnings vs. Estimates